GEN Exclusives

More »

GEN News Highlights

More »
Sep 19, 2006

sanofi pasteur Completes First Clinical Trial Lot of Novel H7N1 Vaccine

  • Within the framework of FLUPAN, a collaborative research project funded by the European Commission, sanofi pasteur generated the first clinical trial lot of a new generation of H7N1 pandemic vaccine. This trial will broaden sanofi pasteur’s pandemic preparedness program initiated with the development of H5N1 vaccines, says the company.

    The H7N1 vaccine was produced at sanofi pasteur’s Marcy l'Etoile facility in France using Crucell’s PER.C6® cell-based technology. The Phase I trial, which just began in Bergen, Norway, is the first to assess the safety and ability to generate an immune response of a split, inactivated prototype pandemic H7N1 vaccine produced on cells.

    Two influenza subtypes, H5 and H7, have recently caused highly pathogenic avian influenza. While most vaccine development has focused on H5N1 strains, many consider avian H7-containing viruses a significant pandemic threat, which has caused infections in humans in Europe over the last three years.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »